Thermo Fisher Scientific | Jan 8, 2024 | 1 min read
Natural killer (NK) cells target infected and oncogenic cells, but are difficult to work with in vitro. Discover novel approaches to producing genetically modified NK cells for cell therapy.
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful.